Highly Sensitive Method Detects Malaria Parasites
|
By LabMedica International staff writers Posted on 18 Mar 2015 |

Image: A gametocyte of Plasmodium falciparum in a thin blood smear and also seen are ring-form trophozoites and a red blood cell exhibiting basophilic stippling (Photo courtesy of Dr. Mae Melvin).
A large proportion of asymptomatic malaria infections can only be identified by surveillance with molecular methods, yet these infections also contribute to onward transmission to mosquitoes.
New molecular assays that take advantage of genes with multiple copies in the parasite genome have been developed that can detect malaria parasites in human blood at very low levels and might be helpful in the campaign to eradicate malaria.
An international team of scientists led by those at the Swiss Tropical and Public Health Institute (Basel, Switzerland) compared three methods to detect malaria parasites in 498 samples randomly selected from a malaria survey in Tanzania: light microscopy, the current standard molecular assay, and the new assays. Two quantitative polymerase chain reaction (qPCR) assays were developed for ultra-sensitive detection of Plasmodium falciparum, targeting the high-copy telomere-associated repetitive element 2 (TARE-2, ~250 copies/genome) and the var gene acidic terminal sequence (varATS, 59 copies/genome).
Parasites were detected in 25% of samples by light microscopy, in 50% by the standard assay, and in 58% by the new assays. Compared to the new assays, the current molecular standard assay failed to identify 16% of infections, and at least 40% of those contained parasite gametocytes, the parasite stage that is transmitted when mosquitoes bite an infected person. Standard PCR is widely considered a molecular gold standard of malaria diagnosis complementing light microscopy, the traditional gold standard, yet these results suggest that this notion requires revision.
The new assays detect only the most common malaria parasite, P. falciparum, and while they can use very small blood samples collected in the field, the analysis itself needs to be done in a biomedical laboratory. Nonetheless, because low-density infections without disease symptoms are expected to become increasingly common as countries improve malaria control, ultra-sensitive tools such as these will likely be critical for malaria surveillance and for monitoring the progress of malaria control and elimination programs. The study was published on March 3, 2015, in the journal Public Library of Science Medicine.
Related Links:
Swiss Tropical and Public Health Institute
New molecular assays that take advantage of genes with multiple copies in the parasite genome have been developed that can detect malaria parasites in human blood at very low levels and might be helpful in the campaign to eradicate malaria.
An international team of scientists led by those at the Swiss Tropical and Public Health Institute (Basel, Switzerland) compared three methods to detect malaria parasites in 498 samples randomly selected from a malaria survey in Tanzania: light microscopy, the current standard molecular assay, and the new assays. Two quantitative polymerase chain reaction (qPCR) assays were developed for ultra-sensitive detection of Plasmodium falciparum, targeting the high-copy telomere-associated repetitive element 2 (TARE-2, ~250 copies/genome) and the var gene acidic terminal sequence (varATS, 59 copies/genome).
Parasites were detected in 25% of samples by light microscopy, in 50% by the standard assay, and in 58% by the new assays. Compared to the new assays, the current molecular standard assay failed to identify 16% of infections, and at least 40% of those contained parasite gametocytes, the parasite stage that is transmitted when mosquitoes bite an infected person. Standard PCR is widely considered a molecular gold standard of malaria diagnosis complementing light microscopy, the traditional gold standard, yet these results suggest that this notion requires revision.
The new assays detect only the most common malaria parasite, P. falciparum, and while they can use very small blood samples collected in the field, the analysis itself needs to be done in a biomedical laboratory. Nonetheless, because low-density infections without disease symptoms are expected to become increasingly common as countries improve malaria control, ultra-sensitive tools such as these will likely be critical for malaria surveillance and for monitoring the progress of malaria control and elimination programs. The study was published on March 3, 2015, in the journal Public Library of Science Medicine.
Related Links:
Swiss Tropical and Public Health Institute
Latest Microbiology News
- Study Highlights Accuracy Gaps in Consumer Gut Microbiome Kits
- WHO Recommends Near POC Tests, Tongue Swabs and Sputum Pooling for TB Diagnosis
- New Imaging Approach Could Help Predict Dangerous Gut Infection
- Rapid Sequencing Could Transform Tuberculosis Care
- Blood-Based Viral Signature Identified in Crohn’s Disease
- Hidden Gut Viruses Linked to Colorectal Cancer Risk
- Three-Test Panel Launched for Detection of Liver Fluke Infections
- Rapid Test Promises Faster Answers for Drug-Resistant Infections
- CRISPR-Based Technology Neutralizes Antibiotic-Resistant Bacteria
- Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
- AI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
- New Test Measures How Effectively Antibiotics Kill Bacteria
- New Antimicrobial Stewardship Standards for TB Care to Optimize Diagnostics
- New UTI Diagnosis Method Delivers Antibiotic Resistance Results 24 Hours Earlier
- Breakthroughs in Microbial Analysis to Enhance Disease Prediction
- Blood-Based Diagnostic Method Could Identify Pediatric LRTIs
Channels
Clinical Chemistry
view channel
Blood Test Tracks Transplant Health Using Donor DNA
Organ transplantation offers life-saving treatment for patients with end-stage disease, but complications such as rejection remain a constant risk. Monitoring transplanted organs typically relies on invasive... Read more
AI Sensor Detects Neurological Disorders Using Single Saliva Drop
Neurological disorders such as Parkinson’s disease and Alzheimer’s disease often develop gradually and present subtle symptoms in their early stages. Because early signs are frequently vague or atypical,... Read moreMolecular Diagnostics
view channel
Blood Test Predicts Dementia in Women 25 Years Before Symptoms Begin
Dementia and Alzheimer’s disease often develop silently over many years before symptoms appear. Detecting risk earlier could allow preventive strategies to begin long before memory problems interfere with... Read more
Serial Liquid Biopsies Reveal Therapy Resistance in Metastatic Prostate Cancer
Metastatic Prostate cancer can rapidly adapt under treatment, making it difficult to detect resistance before clinical progression. Genomic results from archival tumor tissue may no longer reflect the... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response
Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more
Immune Signature Identified in Treatment-Resistant Myasthenia Gravis
Myasthenia gravis is a rare autoimmune disorder in which immune attack at the neuromuscular junction causes fluctuating weakness that can impair vision, movement, speech, swallowing, and breathing.... Read more
New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer
Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read moreBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read morePathology
view channel
Novel mcPCR Technology to Transform Testing of Clinical Samples
DNA methylation is an important biological marker used in the diagnosis and monitoring of many diseases, including cancer. These chemical modifications to DNA influence gene activity and can reveal early... Read more
Sex Differences in Alzheimer’s Biomarkers Linked to Faster Cognitive Decline
Sex differences in Alzheimer’s disease present ongoing diagnostic challenges, with women often experiencing a disproportionate disease burden even when preclinical amyloid-beta levels are similar to men.... Read moreTechnology
view channel
AI Model Outperforms Clinicians in Rare Disease Detection
Rare diseases affect an estimated 300 million people worldwide, yet diagnosis is often protracted and error-prone. Many conditions present with heterogeneous signs that overlap with common disorders, leading... Read more
AI-Driven Diagnostic Demonstrates High Accuracy in Detecting Periprosthetic Joint Infection
Periprosthetic joint infection (PJI) is a rare but serious complication affecting 1% to 2% of primary joint replacement surgeries. The condition occurs when bacteria or fungi infect tissues around an implanted... Read moreIndustry
view channel
MGI Tech Strengthens Sequencing Portfolio with Dual Acquisition
MGI Tech Co., Ltd. (Shenzhen, China) announced the acquisition of STOmics and CycloneSEQ on March 3, 2026, as part of its “SEQALL+GLI+Omics” strategy. According to the company, the combined portfolio spans... Read more
Agilent Technologies Acquires Pathology Diagnostics Company Biocare Medical
Agilent Technologies (Santa Clara, CA, USA) has entered into a definitive agreement to acquire Biocare Medical (Pacheco, CA, USA), expanding its pathology portfolio through the addition of highly complementary... Read more







 Analyzer.jpg)
